安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases
Sarepta is engineering solutions for rare diseases with science that is on the forefront of precision genetic medicine Our platforms include: gene therapy, RNA technologies, and gene editing We are in a daily race to save lives stolen or impacted by rare disease
- About Our Company - Sarepta Therapeutics
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short
- Our Pipeline | Sarepta Therapeutics
Sarepta’s industry leading pipeline is comprised of over 40 programs in various stages of development across 3 technologies, RNA, gene therapy and gene editing, and multiple therapeutic areas including neuromuscular, CNS and cardiology
- News Press Releases - Sarepta Therapeutics
Read news and articles from Sarepta, a global biotechnology company developing potentially life-changing precision genetic medicine
- Investor Relations | Sarepta Therapeutics, Inc.
The Investor Relations website contains information about Sarepta Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
- Our Disease Areas - Sarepta Therapeutics
At Sarepta, we’re committed to pursuing some of the world’s most debilitating, prevalent, and complex rare genetic diseases Today, our primary focus is on Duchenne muscular dystrophy, limb-girdle muscular dystrophies, and Charcot-Marie-Tooth disease
- Products | Sarepta Therapeutics
Call 1-888-SAREPTA (1-888-727-3782) Available Monday through Friday, 8:30am - 6:30pm ET Spanish-speaking Case Managers and interpreters for other languages are available
- Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to . . .
Sarepta extends its deepest sympathies to the affected families and care teams Key Safety Initiatives Evaluating and Enhancing Immunosuppressive Regimen: As part of a comprehensive review of safety data, Sarepta is taking proactive steps to mitigate the risk of acute liver failure in non-ambulatory patients Sarepta is working to immediately
|
|
|